̽»¨Ö±²¥

Biotech firms have developed nearly 40% more of key treatments for unmet medical needs, says a new book co-authored by Cambridge researchers.

Cambridge's Experimental Medicine Initiative, working with AstraZeneca and GSK, is training specialists who can work out at an earlier stage of clinical trials if a treatment is likely to succeed.

Professor Steve Jackson talks about drug discovery, serial entrepreneurship and the enterprising mindset.

Scientists have developed a ‘nanobody’ – a small fragment of a llama antibody – that is capable of chasing out human cytomegalovirus (HCMV) as it hides away from the immune system. This then enables immune cells to seek out and destroy this potentially deadly virus.

̽»¨Ö±²¥Trinity Challenge has announced the winners of its inaugural competition, and is investing a £5.7 million (US$8 million) charitable pledged prize fund into one grand prize winner, two 2nd prize winners, and five 3rd prize winners.

Fitzwilliam College medical student Buraq Ahmed has had more than his fair share of challenges to overcome. Arriving in the UK from Iraq in 2005 for routine medical treatment, he became stranded when the conflict intensified. He shares how his experiences have shaped him – and what it’s like to start university during a global pandemic.

̽»¨Ö±²¥COVID-19 pandemic is the greatest global healthcare crisis of our generation, presenting enormous challenges to medical research, including clinical trials. Advances in machine learning are providing an opportunity to adapt clinical trials and lay the groundwork for smarter, faster and more flexible clinical trials in the future.

A new type of artificial heart valve, made of long-lived polymers, could mean that millions of patients with diseased heart valves will no longer require lifelong blood-thinning medication after valve replacement surgery.

Machine learning and AI are highly unstable in medical image reconstruction, and may lead to false positives and false negatives, a new study suggests.

Repurposing existing medicines focused on known drug targets is likely to offer a more rapid hope of tackling COVID-19 than developing and manufacturing a vaccine, argue an international team of scientists in the British Journal of Pharmacology.